# VentiRx Pharmaceuticals Inc.: Form D filings

VentiRx Pharmaceuticals Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2010 and 2014. The latest, on September 30, 2014, reports $15 million sold of a $15 million offering to 1 investor.

Find out what VentiRx Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20VentiRx%20Pharmaceuticals%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=VentiRx%20Pharmaceuticals%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fventirx-pharmaceuticals-inc-1367762)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20VentiRx%20Pharmaceuticals%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=VentiRx%20Pharmaceuticals%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fventirx-pharmaceuticals-inc-1367762)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Washington](https://specstream.ai/data/form-d/state/washington): 1,095 rows, by operating companies, filed since November 1, 2024, $54.75, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/washington
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 1191 SECOND AVE., SUITE 1105, Seattle, WA, 98101
- Phone: (206) 689-2259
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1367762

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sep 30, 2014 | New notice | $15,000,000 | $15,000,000 | $0 | 1 | Sep 22, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1367762/000136776214000004/0001367762-14-000004-index.htm) |
| Sep 23, 2014 | Amendment | $53,102,414 | $50,602,514 | $2,499,900 | 9 | Jan 8, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1367762/000136776214000003/0001367762-14-000003-index.htm) |
| Mar 8, 2012 | Amendment | $25,000,002 | $18,750,001 | $6,250,001 | 5 | Jan 8, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1367762/000136776212000002/0001367762-12-000002-index.htm) |
| Jan 22, 2010 | New notice | $25,000,002 | $12,500,001 | $12,500,001 | 5 | Jan 8, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1367762/000136776210000003/0001367762-10-000003-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Ron M. Laufer | Director |  |
| Atul M. Saran | Director |  |
| Kathleen M. Fanning | Executive Officer |  |
| Robert M. Hershberg, M.D., Ph.D. | Executive Officer, Director |  |
| Kent M. Snyder | Director |  |
| Steven M. Gillis, Ph.D. | Director |  |
| Patrick M. Heron | Director |  |
| Nicole M. Vitullo | Director |  |

## Other biotechnology companies in Washington that filed recently

- [Key Proteo, Inc.](https://specstream.ai/data/form-d/company/key-proteo-inc-1977784) $2.3 million · Oct 23, 2026
- [Inmedix, Inc.](https://specstream.ai/data/form-d/company/inmedix-inc-1851853) $4 million · Oct 22, 2026
- [Q-Immune, Inc.](https://specstream.ai/data/form-d/company/q-immune-inc-2155816) $25,000 · Sep 28, 2026
- [Hexamer Therapeutics, Inc](https://specstream.ai/data/form-d/company/hexamer-therapeutics-inc-1797915) $500,000 · Sep 15, 2026
- [MalarVx, Inc.](https://specstream.ai/data/form-d/company/malarvx-inc-1559688) $125,000 · Aug 25, 2026
- [Strella Biotechnology, Inc.](https://specstream.ai/data/form-d/company/strella-biotechnology-inc-1810011) $1.8 million · Aug 14, 2026

[Every Form D from the week of Sep 29, 2014](https://specstream.ai/data/form-d/week/2014-09-29) · [All recent filings in Washington](https://specstream.ai/data/form-d/state/washington) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what VentiRx Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).